Premium
Promotion of Myofibroblast Differentiation and Tissue Fibrosis by the Leukotriene B 4 –Leukotriene B 4 Receptor Axis in Systemic Sclerosis
Author(s) -
Liang Minrui,
Lv Jiaoyan,
Jiang Zhixing,
He Hang,
Chen Chen,
Xiong Yinluo,
Zhu Xiaoxia,
Xue Yu,
Yu Yiyun,
Yang Sen,
Wang Lingbiao,
Li Wenjing,
Guan Ming,
Wan Weiguo,
He Rui,
Zou Hejian
Publication year - 2020
Publication title -
arthritis and rheumatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 4.106
H-Index - 314
eISSN - 2326-5205
pISSN - 2326-5191
DOI - 10.1002/art.41192
Subject(s) - myofibroblast , leukotriene b4 , fibrosis , receptor , medicine , bleomycin , immunology , endocrinology , chemistry , inflammation , chemotherapy
Objective To investigate the role of the inflammatory lipid mediator leukotriene B 4 ( LTB 4 ) and its receptor, BLT1, in the development and progression of systemic sclerosis ( SS c). Methods Serum levels of LTB 4 were compared in 64 patients with SS c and 80 healthy controls. Skin and lung tissue sections from patients with SS c and healthy donors were immunostained for leukotriene A 4 hydrolase ( LTA 4 H), the critical enzyme for LTB 4 synthesis, and BLT1, in combination with different cell markers. In mouse models of SS c using bleomycin or angiotensin II challenge or immunization with the DNA topoisomerase I, genetic or pharmacologic interruption of the LTB 4 – BLT1 axis in mice was carried out to assess its effects on systemic disease features and myofibroblast markers. Immunoblotting was performed to examine the signaling pathway in fibroblasts and endothelial cells following stimulation with LTB 4 or with serum from SSc patients. Results Serum LTB 4 levels were 44.93% higher in patients with SS c than in matched healthy controls (mean ± SD 220.3 ± 74.75 pg/ml versus 152.0 ± 68.05 pg/ml; P < 0.0001), and this was associated with the patient subsets of SS c‐associated interstitial lung disease and diffuse cutaneous SS c. Levels of LTA 4 H and BLT1 were increased in lesional areas of the skin and lungs of SS c patients, and both were abundant in myofibroblasts and endothelial cells. Interruption of the LTB 4 – BLT1 axis in mouse models of SS c significantly mitigated dermal and pulmonary fibrosis, with 54.00% and 52.65% fewer α‐smooth muscle actin–positive myofibroblasts accumulating in the skin and lungs of mice, respectively, after bleomycin challenge. Immunoblotting of cultures with recombinant LTB 4 –stimulated fibroblasts and endothelial cells or with serum from SS c patients showed that fibroblast–myofibroblast and endothelial–mesenchymal transitions were promoted via BLT1, and that this was dependent on activation of the phosphatidylinositol 3‐kinase ( PI 3K)/Akt/mechanistic target of rapamycin ( mTOR ) pathway but independent of the release of transforming growth factor β ( TGF β) by fibroblasts or endothelial cells. Conclusion The LTB 4 – BLT1 axis may contribute to fibrosis in SS c by directly promoting myofibroblast differentiation via the PI 3K/Akt/ mTOR pathway, and this appears to operate independently of autocrine secretion of TGF β.